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___________________________________________________________________ 
 
Given the complexity of the approximately seven hundred pages that make up the 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, we are 
providing a snapshot summary describing the legislation’s impact on the key 
stakeholders. 
 
Medicare Beneficiaries 
 
In general, there is a significant expansion of benefits in terms of pharmacy benefits, 
managed care plan options, and preventive care coverage. Medicare will now cover 
initial preventative physical examinations in addition to screening services such as 
pelvic exams, prostate cancer screening, colorectal cancer screening, diabetes 
outpatient self-management, bone mass measurement, glaucoma screening, and 
cardiovascular and diabetes screening tests. There are also demonstration programs 
scheduled for certain new benefits which include additional chiropractic services, 
adult day care services, consumer-directed chronic outpatient services, continuity 
care for chronic patients, small provider technical assistance services, beneficiary 
outreach services through Social Security offices, and pediatric palliative care. 
 
Managed Care Plans 
 
The Medicare+Choice program is renamed the Medicare Advantage program. There 
are both near-term payment increases as well as additional funds totaling $12 billion 
to entice plans into the Medicare Advantage program beginning in 2006. Despite 
these positive improvements, it is important to remember that the government has 
not always been a great business partner. The concern is that tight budgets would 
lead to payment cuts and revisions that would reduce the attractiveness of 
participating in the Medicare Advantage program in the future. 
 
Physicians 
 
Rather than the expected 4.5% payment cut due in 2004, physicians will see a 
minimum payment increase of 1.5% in 2004 and 2005. For oncologists and others 
that provide Medicare-covered drugs, Medicare payment for Part B-covered drugs 
will be reduced from the current 95% of average wholesale price to 106% of average 
sales price.  In addition, payments could be reduced further to a “widely available 
market price” where appropriate. 
 
Rural Physicians 
 
The bill provides for a substantial increase for rural physicians in the form of a floor 
on physician geographic work index, which will result in approximately one billion 
dollars in additional payments over ten years. There is also a five percent bonus for 
physician payments in “scarcity areas.” 
 
Pharmaceutical Manufacturers 
 
As a result of the Medicare Pharmacy Benefit, there will be an increase in the 
demand for both name brand and generic medications. In addition, the bill 
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specifically prohibits the federal government from imposing price controls and limits 
the ability of prescription drug plans to control utilization through formulary 
restrictions. It allows drug re-importation from Canada only, and only after the 
Secretary of Health and Human Services certifies that reimportation is safe and 
provides for cost savings—a move that is unlikely to happen. 
 
Hospitals 
 
Hospitals that agree to submit quality outcome data to the Centers for Medicare and 
Medicaid Services will receive a full market basket update for the next several years. 
Graduate medical education payments will be reduced through the expansion of the 
limitation on high cost programs, although indirect medical education subsidy 
payments are increased by $400 million. 
 
Long-term Care (LTC) Facilities 
 
LTC facilities may experience some benefits as a result of Medicare relieving the 
state burden of a percentage of their prescription drug costs now that Medicare is the 
payor for prescriptions rather than Medicaid. In addition, the therapy cap will not be 
applied for at least two years. 
 
Hospice Agencies 
 
Nurse practitioners will now be recognized as attending physicians for hospice 
patients. Also, hospice consultation services provided by a physician will be covered 
under Medicare. Examples of these services include evaluating for pain and symptom 
management, counseling with respect to end-of-life care, and advising on advanced 
care planning. 
 
Home Health Agencies 
 
In addition to a decrease in payments, there is additional concern for future Medicare 
payments, as the bill calls for MedPAC to study home health profit margins, which is 
expected to result in further cuts. On a slightly positive note, Medicare has 
suspended the requirement for OASIS data collection for non-Medicare and Medicaid 
patients. 
 
Ambulatory Surgical Centers (ASC) 
 
ASCs will see an immediate payment reduction, as well as a long-term freeze in 
payments rates. In addition, ASCs will move toward a new prospective payment 
system.   
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